Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc., an emerging growth company, filed this Form 8-K on January 24, 2019, reporting events occurring on January 24 and January 25, 2019. The filing primarily announces the entry into a material definitive agreement for a public offering of common stock.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, or operating margins. The primary financial data relates to the proposed capital raise:
- Shares Offered: 5,390,000 shares of common stock.
- Offering Price: $6.50 per share.
- Expected Net Proceeds: Approximately $32.7 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters hold a 30-day option to purchase up to 808,500 additional shares.
Material Changes
The material change reported is the execution of an underwriting agreement with Jefferies LLC and RBC Capital Markets, LLC. This agreement facilitates the sale of the shares described above. The filing notes that the offering is expected to close on or about January 29, 2019, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the offering and the expectation of closing. The filing includes standard forward-looking statement disclaimers regarding the anticipated closing and proceeds. Key risks identified include the Company's ability to satisfy closing conditions in a timely manner or at all. The filing references the Company's Form 10-K filed on March 12, 2018, and the prospectus supplements for a detailed discussion of other risks.
Investor Verification Checklist
- Verify the final closing date of the offering, as the filing states it is expected "on or about January 29, 2019."
- Confirm the final net proceeds, as the $32.7 million figure is an estimate subject to actual offering expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Check subsequent filings to determine if the underwriters exercised the 30-day option to purchase the additional 808,500 shares.